Drug Trial Radar · NCT04181788
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
155
Actual
Start
Mar 18, 2020
Primary completion
Mar 3, 2022
Study completion May 13, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies. This study consists of 2 parts: Phase 1b part (dose escalation and dose expansion) in patients with advanced malignancies in Asia and a global Phase 2 part in non small cell lung cancer (NSCLC) patients.
Conditions
- Advanced Malignancies
- Non-small-cell Lung Cancer
Interventions
PF-06801591Drug
A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)Time frame: Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms
- Phase 2: AUCτ of PF-06801591 at Steady StateTime frame: Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm
- Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12Time frame: Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm
Locations
49 sites in 6 countries. Site status is shown where the registry gives one.
Beijing Cancer hospital
Beijing, Beijing Municipality, China
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Evimed Llc
Chelyabinsk, Russia
Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine
Chelyabinsk, Russia
Ars Medika Center, LLC
Kaliningrad, Russia
GBUZ Regional Clinical Hospital of Kaliningrad region
Kaliningrad, Russia
Enlimed Llc
Kopeysk, Russia
Orenburg Regional Clinical Oncological Dispensary
Orenburg, Russia
Russian Scientific Center For Radiology and Surgical Technologies
Pesochny, Russia
LLC Medical Center "Magnit"
Saint Petersburg, Russia
Llc "Mss"
Saint Petersburg, Russia
North-West Medical Center
Saint Petersburg, Russia
Road clinical clinic of JSC "RZD"
Saint Petersburg, Russia
NS HI "Road Clinical Hospital of JSC "Russian Railways""
Saint Petersburg, Russia
Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of St. Petersburg
Saint Petersburg, Russia
LLC "Diagnostic center "Energo"
Saint Petersburg, Russia
Medical University REAVIZ
Samara, Russia
Medical University REAVIZ
Samara, Russia
Russian Research Centre for Radiology and Surgical Technologies
Saint Petersburg, Pesochny, Russia
Private Medical Institution "Euromedservice"
Pushkin, Sankt-Peterburg, Russia
Klinika UZI 4D, LLC
Pyatigorsk, Stavropol Kray, Russia
State budgetary institution of healthcare of Yaroslavl region "Clinical oncology hospital"
Yaroslavl, Yaroslavl Oblast, Russia
Gachon University Gil Medical Center
Incheon, South Korea
Severance Hospital, Yonsei Univ. Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Communal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council
Dnipro, Ukraine
LLC "AR DI PI Ukraine"
Dnipro, Ukraine
Llc "Mdc Expert"
Dnipro, Ukraine
Municipal Non-profit Enterprise "SubCarpathian Clinical Oncological Centre of Ivano-Frankivsk RC"
Ivano-Frankivsk, Ukraine
Private Enterprise of Private Manufacturing Company "Acinus", Medical and Diagnostic Center
Kropyvnytskyi, Ukraine
Medical centre "Verum" Limited Liability Company
Kyiv, Ukraine
Vita Сom LLC
Kyiv, Ukraine
The State Institution "Romodanov Neurosurgery Institute,
Kyiv, Ukraine
Llc Medical Centre
Odesa, Ukraine
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.